Medical Advocates
HIV/HCV Coinfection
 
Antiretroviral Drugs

HAART/ART: General Reports    Peginterferons
Atazanavir
Darunavir
Didanosine
Efavirenz
Fosamprenavir
Lopinavir
Nelfinavir
Nevirapine
Stavudine
Tenofovir
Zidovudine
HIV/HCV Main Page New/Newsworthy Home Page
Last Update:  August 03, 2008  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
HAART/ART General Reports
 

    Journal Papers, Abstracts, and Commentaries
 
 
Effect of Antiretroviral Therapy and Hepatitis C Co-infection on Changes in Lipid Levels in
HIV-Infected Patients 48 Weeks After Initiation of Therapy.
 Stapleton JT, Bennett K, Bosch RJ, et al 
HIV Clin Trials. 2007 Nov-Dec;8(6):429-36.
 Abstract
 
Case Report: Hepatitis C Virus Activation in HIV-Infected Patients Initiating Highly Active
Antiretroviral Therapy.
 Kim HN, Harrington RD, Shuhart MC, et al 
AIDS Patient Care STDS. 2007 Oct;21(10):718-23.
 Abstract
 
Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and
HIV-HCV infection.
 Cooper CL, Mills E.
Int J STD AIDS. 2007 Aug;18(8):546-50.
 Abstract
 
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency
virus-infected patients undergoing highly active antiretroviral therapy.
 Pineda JA, García-García JA, Aguilar-Guisado M, et al
Hepatology. 2007 Jul 20;
Abstract
 
Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy.
Zeitoun JD, Mallet V, Chaix ML, et al
J Clin Virol. 2007 Jul 18;
 Abstract
 
Early Initiation of Antiretroviral Therapy: The Current Best Way to Reduce Liver-Related
Deaths in HIV/Hepatitis C Virus-Coinfected Patients.
Shafran SD
 J Acquir Immune Defic Syndr. 2007 Jan 11;
 Abstract
 
Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV
and Hepatitis C Coinfection Using a Noninvasive Marker.
 Al-Mohri H, Murphy T, Lu Y,
J Acquir Immune Defic Syndr. 2007 Jan 4;
Abstract
 
Antiretroviral Medication Considerations for Individuals Coinfected with HIV and
Hepatitis C Virus.
 Lai AR, Tashima KT, Taylor LE.
AIDS Patient Care STDS. 2006 Oct;20(10):678-92.
 Abstract
 
Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection.
 Parsons TD, Tucker KA, Hall CD, et al 
AIDS. 2006 Aug 1;20(12):1591-5.
 Abstract
 
HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
 Verma S.
J Antimicrob Chemother. 2006 Jul 19;
Abstract
 
Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral
therapy.
 Sullivan PS, Hanson DL, Teshale EH, et al
AIDS. 2006 May 12;20(8):1171-1179.
 Abstract
 
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at
an Haemophilia Unit during a decade.
Sauleda S, Martorell M, Esteban JI,
 Haemophilia. 2006 May;12(3):228-36
 Abstract
 
Impact of Hepatitis C Virus Coinfection on Response to Highly Active Antiretroviral Therapy
and Outcome in HIV-Infected Individuals: A Nationwide Cohort Study.
 Weis N, Lindhardt BO, Kronborg G, et al 
Clin Infect Dis. 2006 May 15;42(10):1481-7.
 Abstract
 
Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients.
Guitton E, Montastruc JL, Lapeyre-Mestre M;
Eur J Clin Pharmacol. 2006 Jan 17;
 Abstract
 
Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C
irus-coinfected patients?
 Verma S, Wang CH, Govindarajan S, et al 
Clin Infect Dis. 2006 Jan 15;42(2):262-70.
 Abstract
 
Immunologic Response to Antiretroviral Therapy in Hepatitis C Virus-Coinfected Adults in a
Population-Based HIV/AIDS Treatment Program.
Braitstein P, Zala C, Yip B, et al
 J Infect Dis. 2006 Jan 15;193(2):259-68.
 Abstract
 
Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection.
 Cooper C, Breau C, Laroche A, et al
HIV Med. 2006 Jan;7(1):32-7.
 Abstract
 
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
 Brau N.
J Antimicrob Chemother. 2005 Nov 24;
Abstract
 
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression
using antiretroviral therapy.
 Brau N, Salvatore M, Rios-Bedoya CF, et al 
J Hepatol. 2005 Sep 20;
Abstract

Impact of Hepatitis C Virus on Immune Restoration in HIV-Infected Patients Who Start Highly
Active Antiretroviral Therapy: A Meta-analysis.
 Miller MF, Haley C, Koziel MJ, Rowley CF
Clin Infect Dis. 2005 Sep 1;41(5):713-20.
 Abstract
 
Effects of Hepatitis C Virus Coinfection on Survival in Veterans With HIV Treated With
Highly Active Antiretroviral Therapy.
 Backus LI, Phillips BR, Boothroyd DB
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):613-619.
Abstract
 
FULL-TEXT ARTICLE
 Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in
HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C, Lapadula G, Casari S, et al  
BMC Infect Dis. 2005 Jul 14;5(1):58
 Paper
 
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen:
increased incidence of stopping due to toxicity or patient/physician choice in patients with
hepatitis C coinfection.
Mocroft A, Phillips AN, Soriano V, et al
AIDS Res Hum Retroviruses. 2005 Jun;21(6):527-36.
 Abstract
 
Liver enzymes elevation after HAART in HIV-HCV co-infection.
 Servin-Abad L, Molina E, Baracco G, et al  
J Viral Hepat. 2005 Jul;12(4):429-34.
 Abstract
 
Influence of Liver Fibrosis on Highly Active Antiretroviral Therapy-Associated Hepatotoxicity
in Patient swith HIV and Hepatitis C Virus Coinfection.
 Aranzabal L, Casado JL, Moya J, et al
 Clin Infect Dis. 2005 Feb 15;40(4):588-93.
 Abstract
 
The effect of antiretroviral therapy on liver disease among adults with HIV and
hepatitis C coinfection.
 Mehta SH, Thomas DL, Torbenson M, et al 
Hepatology. 2004 Dec 23;41(1):123-131
 Abstract
 
Hepatitis C Virus Coinfection Increases Mortality in HIV-Infected Patients in the Highly
Active Antiretroviral Therapy Era: Data from the HIV Atlanta VA Cohort Study.
 Anderson KB, Guest JL, Rimland D, et al  
Clin Infect Dis. 2004 Nov 15;39(10):1507-13.
 Abstract
 
Hepatitis C Virus Coinfection Increases Mortality in HIV-Infected Patients in the Highly
Active Antiretroviral Therapy Era: Data from the HIV Atlanta VA Cohort Study.
 Anderson KB, Guest JL, Rimland D, et al  
Clin Infect Dis. 2004 Nov 15;39(10):1507-13.
 Abstract
 
The effect of hepatitis C on progression to AIDS before and after highly active
antiretroviral therapy.
 Dorrucci M, Valdarchi C, Suligoi B, et al 
AIDS. 2004 Nov 19;18(17):2313-2318.
 Abstract
 
HIV Infection, hepatitis C infection, and HAART: hard clinical choices.
 Kottilil S, Polis MA, Kovacs JA. et al 
JAMA. 2004 Jul 14;292(2):243-50.
 Abstract
 
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease
progression in the HIV-NAT cohort.
 Law WP, Duncombe CJ, Mahanontharit A,et al 
AIDS. 2004 May 21;18(8):1169-1177.
 Abstract
 
Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
 Bonacini M.
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S104-8.
 Abstract
 
Impact of highly active antiretroviral therapy on the spectrum of liver disease in hcv-hiv
coinfection.
 Sterling RK, Wilson MS, Sanyal AJ, et al 
Clin Gastroenterol Hepatol. 2004 May;2(5):432-9
 Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C:
harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
 AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
 
Antiretroviral Therapy in Patients with Hepatitis and HIV: Weighing Risks and Benefits.
 Powderly WG.  
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S109-13.
 Abstract
 
The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune
response.
 Herrero-Martinez E, Sabin CA, et al
J Med Virol. 2004 Feb;72(2):187-93
 Abstract

Impaired Recovery of CD4+ Cell Counts Following Highly Active Antiretroviral Therapy in
Drug-Naive Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
 Macias J, Pineda JA, Lozano F, et al
Eur J Clin Microbiol Infect Dis. 2003 Oct 23
Abstract
 
Effect of HAART on HCV viral load in the first three years of follow-up
 Tornero C, Gimeno C, Igual R, et al 
Drug Alcohol Depend. 2003 Oct 24;72(1):13-21
 Abstract
 
The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active
Antiretroviral Therapy.
Klein MB, Lalonde RG, Suissa S.
Acquir Immune Defic Syndr. 2003 Jul 1;33(3):365-372.
Abstract

Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus
quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.
 Babik JM, Holodniy M.
J Virol 2003 Feb;77(3):1940-50
 Abstract

Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA
levels in human immunodeficiency virus and HCV coinfection.
Cooper CL, Cameron DW.
Clin Infect Dis 2002 Oct 1;35(7):873-9
 Abstract

  

     Conference Reports, Abstracts, and Posters

 
Impact of different ART regimens on efficacy and safety of standard HCV treatment in
HIV/HCV co-infected patients
 Khaykin P, Vogel M, Voigt E, Rockstroh J, et al
 (4th IAS Conference)
 Abstract
 
Factors Associated with High HCV Viral Load in HIV/HCV Co-infected Patients: Is There a
Different Effect between PI and Non-PI-based ART?
 F Bani-Sadr, I Goderel, P Morand, et al
 (14 CROI)
 Abstract
 
POSTER
 Progression after Initiating ART Combination Therapy in HIV/HCV-co-infected Patients According
to Different Baseline CD4+ Cell Count Strata
 F Dronda, J Zamora, C Quereda, et al
(14 CROI)
 PDF Poster   Abstract
 
POSTER
 HAART Reduces the Fibrosis Progression Rate and the Development of Bridging Fibrosis and
Cirrhosis in HIV/HCV-co-infected Patients
 S Resino, Juan Berenguer, P Miralles,. et al
 (14 CROI)
 PDF Poster   Abstract
 
POSTER
 Clinical Progression of Hepatitis C Virus-related Chronic Liver Disease in HIV-infected Patients
Undergoing HAART
 JA García-García, M Aguilar-Guisado, M Ríos-Villegas, et al
 (14 CROI)
 PDF Poster   Abstract

POSTER
 Pharmacokinetics of Boosted PI and NNRTI in HCV/HIV-co-infected Patients
 D Breilh, S Guinguené, V de Lédinghen, et al
(14 CROI)
 PDF Poster   Abstract
 
The Influence of Genotype 3 Hepatitis C Co-Infection on Liver Enzyme Elevations in HIV-
Infected Patients after Commencement of a New HAART: Results from the MASTER-
EPOKA Cohort   
 C. TORTI, M. PUOTI , G. LAPADULA , et al
(45 ICAAC)
Abstract
 
Risk of Haart-Associated Hepatotoxicity in HIV/HCV Co-Infected Patients with Cirrhosis
 L. ARANZABAL, J.L. CASADO, J. MOYA, et al
(45 ICAAC)
Abstract
 
Hepatotoxicity in HIV-Infected Patients Starting HAART
L. ARANZABAL, J L. CASADO, P. DOMINGO, et al 
(45 ICAAC)
Abstract
 
POSTER
Virologic and immunologic response to antiretroviral therapy among HIV patients
co-infected with hepatitis C virus (HCV) - analysis of a 6,401 HIV patient cohort.
BJ Cowling, CA Donnelly, AC Ghani et al  
(XV International AIDS Conference)
 PDF Poster    Abstract

HAART-associated Hepatotoxicity in HIV/HCV Co-infected Patients: Correlation with
Liver Histologic Stage
 J Moya, L Aranzabal, J L Casado, et al  
(11 CROI)
 Abstract
Atazanavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients
co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
    Conference Reports, Abstracts, and Posters
 
  Pharmacokinetics of atazanavir in HIV-1-HCV co-infected patients
 Gatti F, Nasta P, Matti A, et al
(4th IAS Conference)
 Abstract
Darunavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in
Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007 Jul-Aug;8(4):213-20.
 Abstract
Didanosine
 

     Journal Papers, Abstracts, and Commentaries

 
Nucleoside analogues and mitochondrial toxicity.
 Fleischer R, Boxwell D, Sherman KE. 
Clin Infect Dis. 2004 Apr 15;38(8):e79-80
 Abstract

Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity
against HIV-1 and hepatitis C virus.
 Klein MB, Campeol N, Lalonde RG, et al.  
 AIDS 2003 May 2;17(7):1001-1008
 Abstract

  
Efavirenz
     
     Journal Papers, Abstracts, and Commentaries
 
 
Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV
-Coinfected Patients.
 Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
 J Acquir Immune Defic Syndr. 2008 Jul 23.
Abstract

Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM
of EFV.
 Katsounas A, Frank A, Klinker H, Langmann P. 
Eur J Med Res. 2007 Aug 16;12(8):331-6
 Abstract
Fosamprenavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir
and correlation with plasma levels.
Spagnuolo V, Gentilini G, De Bona A, et al
New Microbiol. 2007 Jul;30(3):279-82.
 Abstract
Lopinavir
 

     Journal Papers, Abstracts, and Commentaries

 
Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or Without Cirrhosis.
 Micheli V, Regazzi M, Dickinson L,
Ther Drug Monit. 2008 Jun;30(3):306-313
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients
without Liver Function Impairment : Influence of Liver Fibrosis.
 Molto J, Valle M, Blanco A, Negredo E, et al
Clin Pharmacokinet. 2007;46(1):85-92.
 
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus-Coinfected Subjects With
Hepatic Impairment.
Peng JZ, Pulido F, Causemaker SJ, et al
J Clin Pharmacol. 2006 Mar;46(3):265-74.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with
protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected
patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, et al
Clin Infect Dis. 2005 Oct 15;41(8):1186-95.
 Abstract

    Conference Reports, Abstracts, and Posters

  POSTER
 Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r
or Nelfinavir-based Therapy
KE Sherman, NJ Shire, P Cernohous, et al.
 1l CROI
 PDF Poster
Nelfinavir
 

     Journal Papers, Abstracts, and Commentaries

  Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with
protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected
patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, et al
Clin Infect Dis. 2005 Oct 15;41(8):1186-95.
 Abstract

     Conference Reports, Abstracts, and Posters

  POSTER
 Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r
or Nelfinavir-based Therapy
KE Sherman, NJ Shire, P Cernohous, et al.
(1l CROI)
 PDF Poster
Nevirapine
 

   Journal Papers, Abstracts, and Commentaries

Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in
Patients with HIV and Hepatitis C Virus Coinfection.
 Berenguer J, Bellón JM, Miralles P, et al  
Clin Infect Dis. 2008 Jan 1;46(1):137-43.
 Abstract
 
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis
C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E, Gutiérrez S, Jahnke N, et al
 AIDS. 2007 Jul 31;21(12):1561-156
 Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C:
harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
Stavudine
 

     Conference Reports, Abstracts, and Posters

Population Prevalence of Hepatic Steatosis among Antiretroviral-experienced HCV/HIV
Co-infected Adults with and without Stavudine Exposure
 M Sulkowski, S Mehta, R Moore, M Torbenson, et al
 (15th CROI)
Abstract
Tenofovir
 

     Conference Reports, Abstracts, and Posters

Renal toxicity in HIV/Hepatitis C co-infected individuals exposed to tenofovir and/or Ribavarin
Jones R., Bower M., Mandalia S., et al
(XVI  International AIDS Conference)
Abstract
Zidovudine
 

     Journal Papers, Abstracts, and Commentaries

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during
HCV treatment in HIV-infected persons.
Alvarez D, Dieterich DT, Brau N, ryasl
 J Viral Hepat. 2006 Oct;13(10):683-9
 Abstract

HIV/HCV Main Page New/Newsworthy Home Page

Antiretroviral Drugs